Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Viridian Therapeutics (NASDAQ:VRDN)

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Viridian Therapeutics (NASDAQ:VRDN)

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday. Analyst Lachlan Hanbury-Brown writes that the company's anti-IGF-1R franchise represents a meaningful advance compared to Amgen Inc.’s (NASDAQ:AMGN) Tepezza (teprotumumab-trbw) for thyroid eye disease (TED). TED is a rare autoimmune disorder characterized by inflammation and swelling of the tissues around the eyes, often leading to pain, vision impairment.…

Analysts’ Recent Ratings Updates for Viridian Therapeutics (VRDN)

Several analysts have recently updated their ratings and price targets for Viridian Therapeutics (NASDAQ: VRDN): 12/3/2025 – Viridian Therapeutics is now covered by analysts at William Blair. They set an “outperform” rating on the stock. 12/3/2025 – Viridian Therapeutics was given a new $47.00 price target on by analysts at William Blair. 11/24/2025 – Viridian […]